Publications by authors named "N Chaiyakunapruk"
Article Synopsis
- The review examined cost-effectiveness analyses of new adult pneumococcal vaccines (PCV15 and PCV20) across different countries.
- Most studies found that PCV20 offered cost savings or was more cost-effective than older vaccination strategies in high-income countries.
- Assumptions about vaccine effectiveness, duration of protection, and herd immunity effects varied, with most studies considered low-risk for bias.
Background: Globally, herpes simplex virus (HSV)-2 and -1 infections contribute to a large disease burden, but their full economic consequences remain unclear. This study aims to estimate the global economic impact of genital HSV-2 and HSV-1 infection and its consequences for people with genital ulcer disease, neonatal herpes, and human immunodeficiency virus (HIV) infection attributable to HSV-2.
Methods: Using a societal perspective, the economic burden was calculated at the country level and presented by World Health Organization (WHO) regions and World-Bank income levels.
Background: Although innovation generally provides measurable improvements in disease characteristics and patient survival, some benefits can remain unclear. This study aimed to investigate patient and healthcare provider (HCP) preferences for the innovative attributes of multiple myeloma (MM) treatments.
Methods: A cross-sectional, web-based, discrete choice experiment (DCE) survey was conducted among 200 patients with MM and 30 HCPs of patients with MM in the USA.
Article Synopsis
- This systematic review investigates the cost-effectiveness of brexu-cel, a treatment for mantle cell lymphoma and acute lymphoblastic leukemia, across different countries.
- A thorough search was conducted, leading to the review of 149 records, of which 22 were fully analyzed, resulting in five articles and seven health technology assessment (HTA) reports meeting the criteria.
- The findings indicate that brexu-cel is deemed cost-effective in several studies, particularly in Scotland, but some HTA agencies expressed doubts about its cost-effectiveness for certain conditions.
Gout is the most common inflammatory arthritis, affecting approximately 5.1% of adults in the United States (US) population. Gout is a metabolic and autoinflammatory disease.
View Article and Find Full Text PDF